Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Change in Account Payables (2019 - 2025)

Cyclerion Therapeutics has reported Change in Account Payables over the past 7 years, most recently at $18000.0 for Q3 2025.

  • Quarterly results put Change in Account Payables at $18000.0 for Q3 2025, up 12.5% from a year ago — trailing twelve months through Sep 2025 was $176000.0 (up 220.55% YoY), and the annual figure for FY2024 was -$445000.0, up 74.89%.
  • Change in Account Payables for Q3 2025 was $18000.0 at Cyclerion Therapeutics, up from -$21000.0 in the prior quarter.
  • Over the last five years, Change in Account Payables for CYCN hit a ceiling of $1.3 million in Q4 2022 and a floor of -$2.1 million in Q2 2023.
  • Median Change in Account Payables over the past 5 years was $18000.0 (2025), compared with a mean of -$16105.3.
  • Biggest five-year swings in Change in Account Payables: skyrocketed 1379.63% in 2022 and later plummeted 931.05% in 2023.
  • Cyclerion Therapeutics' Change in Account Payables stood at $965000.0 in 2021, then skyrocketed by 37.31% to $1.3 million in 2022, then crashed by 70.94% to $385000.0 in 2023, then tumbled by 77.66% to $86000.0 in 2024, then tumbled by 79.07% to $18000.0 in 2025.
  • The last three reported values for Change in Account Payables were $18000.0 (Q3 2025), -$21000.0 (Q2 2025), and $93000.0 (Q1 2025) per Business Quant data.